SAKAR HEALTHCARE LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 350.6 INR | -0.82% |
|
-2.57% | -12.35% |
| Sales 2022 | 1.29B 15.48M 1.23B | Sales 2023 | 1.34B 16.09M 1.28B | Capitalization | 3.82B 45.8M 3.65B |
|---|---|---|---|---|---|
| Net income 2022 | 152M 1.82M 145M | Net income 2023 | 128M 1.53M 122M | EV / Sales 2022 | 2.46 x |
| Net Debt 2022 | 857M 10.28M 819M | Net Debt 2023 | 1.16B 13.87M 1.11B | EV / Sales 2023 | 3.71 x |
| P/E ratio 2022 |
15.2
x | P/E ratio 2023 |
29.2
x | Employees | 297 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.82% | ||
| 1 week | -2.57% | ||
| Current month | -4.79% | ||
| 1 month | -6.11% | ||
| 3 months | -18.43% | ||
| 6 months | +4.83% | ||
| Current year | -12.35% |
1 week
347.65
371.40
1 month
347.65385.00
Current year
329.00479.00
1 year
210.00479.00
3 years
103.35479.00
5 years
44.00479.00
10 years
44.00479.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 33 | 31/05/12 | |
| Chief Executive Officer | 64 | 25/03/04 | |
| Director of Finance/CFO | 58 | 30/10/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 27/09/20 | |
| Director/Board Member | 63 | 31/03/15 | |
| Founder | 59 | 25/03/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 350.6 | -0.82% | 17 006 |
| 29/04/24 | 353.6 | -0.53% | 9,963 |
| 26/04/24 | 355.4 | +0.28% | 9,234 |
| 25/04/24 | 354.4 | -3.84% | 34,181 |
| 24/04/24 | 368.6 | +2.42% | 14,204 |
Delayed Quote NSE India S.E., April 30, 2024 at 11:21 am
More quotes
Sakar Healthcare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company is engaged in providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules, vials and lyophilized injections, oral solid dosages, and research and development of these products. The Companyâs products include Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid and Lyophilised Injections (In Vials). The Company operates as a contract development and manufacturing organization (CDMO). The Company has approximately 321 product registrations in various countries. The manufacturing unit has been accredited by regulatory authorities of 14 countries, which includes Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, Cote DâIvoire.
Sector
Pharmaceuticals
Calendar
26/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.35% | 80.67M | |
| +3.33% | 69.85B | |
| +11.77% | 8.98B | |
| -14.44% | 4.89B | |
| +41.60% | 4.44B | |
| +5.96% | 3.95B | |
| +21.52% | 2.49B | |
| -19.32% | 2.4B | |
| -27.04% | 2.28B | |
| +7.97% | 1.96B |
- Stock Market
- Equities
- SAKAR Stock
